{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-26-000058","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2026-08-03T11:04:02+00:00","discovered_at":"2026-08-03T11:05:00.299865+00:00","generated_at":"2026-08-03T11:05:05.496378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech Q2 2026 revenue $119.2M (+24% YoY); net income $54.8M; cash $1.1B","bullets":["Q2 2026 VYJUVEK global revenue $119.2M, up 24% YoY; gross margin 95%.","Net income $54.8M ($1.85 basic EPS) vs $38.3M ($1.33) in Q2 2025.","Cash and investments $1.1B; FY 2026 non-GAAP R&D+SG&A guidance $175-195M.","KB803 (ophthalmology) IOLITE study fully enrolled; top-line data expected 4Q 2026.","KB407 (CF) interim results expected before year end; FDA alignment on registrational study design expected 4Q 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-26-000058","json":"https://secwatch.observer/filing/0001711279-26-000058.json","markdown":"https://secwatch.observer/filing/0001711279-26-000058.md","text":"https://secwatch.observer/filing/0001711279-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/0001711279-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/krys-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:05:05.496378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}